MCTA vs CANG vs CLOV vs ACMR vs BTBT

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 6. 1x versus Charming Medical Limited Class A Ordinary Shares at 414. 5x. On forward P/E, ACM Research, Inc. is actually cheaper at 32. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Charming Medical Limited Class A Ordinary Shares (MCTA) delivered a total return of +319.

3%, compared to -79. 8% for Bit Digital, Inc. (BTBT). Over 10 years, the gap is even starker: ACMR returned +32. 7% versus CLOV's -67. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Clover Health Investments, Corp.

(CLOV) is the lower-risk stock at 1. 26β versus Bit Digital, Inc. 's 3. 41β — meaning BTBT is approximately 172% more volatile than CLOV relative to the S&P 500. On balance sheet safety, Bit Digital, Inc. (BTBT) carries a lower debt/equity ratio of 3% versus 24% for Charming Medical Limited Class A Ordinary Shares — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCTA leads at 22. 3% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — MCTA leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACM Research, Inc.

(ACMR) trades at 32. 4x forward P/E versus 92. 7x for Clover Health Investments, Corp. — 60. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANG: 414. 9% to $3. 00.

In this comparison, BTBT (0.

3% yield), ACMR (0. 2% yield) pay a dividend. MCTA, CANG, CLOV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Clover Health Investments, Corp.

(CLOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLOV: -67. 8%, BTBT: -57. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MCTA (Healthcare) and CANG (Consumer Cyclical) and CLOV (Healthcare) and ACMR (Technology) and BTBT (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MCTA is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; CLOV is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; BTBT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.